文献速递骨软组织肉瘤与黑色素瘤

黑色素瘤随机安慰剂对照生物标志物分层Ib期微生物组调节:抗生素预处理对微生物组与免疫的影响

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
PubMed 文献 · Cancer Discov · 2024-01-01

在多中心、随机、安慰剂对照、生物标志物分层的Ib期试验中,未经免疫检查点阻断(ICB)的转移性黑色素瘤患者按基线瘤胃球菌科丰度高低分层,随机接受SER-401方案或安慰剂方案。14例可分析患者中,SER-401联合纳武利尤单抗安全,SER-401组总缓解率25%,安慰剂组67%,但研究因COVID-19疫情期间入组不佳而把握度不足。万古霉素预处理与肠道微生物组破坏和免疫受损相关,ICB给药时未完全恢复。

要点

  • SER-401联合纳武利尤单抗在转移性黑色素瘤患者中安全。
  • SER-401组总缓解率25%,安慰剂组67%,研究因入组不佳把握度不足。
  • 万古霉素预处理与肠道微生物组破坏和免疫受损相关,ICB给药时未完全恢复。

核心结论

  • SER-401联合纳武利尤单抗在黑色素瘤患者中安全,但研究因疫情期间入组不佳而受限。
  • 万古霉素预处理与肠道微生物组破坏和免疫受损相关,尤其在高基线瘤胃球菌科患者中ICB给药时未完全恢复。
  • 作者认为设计此类微生物组调节试验时应仔细考虑抗生素预处理和干预药物给药方案。

研究设计与样本

  • 多中心、随机、安慰剂对照、生物标志物分层的Ib期试验(NCT03817125)。
  • 入组未经ICB的转移性黑色素瘤患者,基线按瘤胃球菌科丰度高 versus 低分层。
  • SER-401组分为口服万古霉素预处理/SER-401单药/纳武利尤单抗+SER-401;安慰剂组分为安慰剂抗生素/安慰剂微生物组调节(PMM)/纳武利尤单抗+PMM。
  • 共14例可分析患者。

主要发现

  • SER-401联合纳武利尤单抗安全。
  • SER-401组总缓解率25%,安慰剂组总缓解率67%。
  • 万古霉素预处理与肠道微生物组破坏和免疫受损相关,ICB给药时未完全恢复,尤其在高基线瘤胃球菌科患者中。

临床怎么用

  • 作者认为设计微生物组调节试验时应仔细考虑抗生素预处理和干预药物给药方案。

局限性

  • 研究因COVID-19疫情期间入组不佳而把握度不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Gut-microbiota modulation shows promise in improving immune-checkpoint blockade (ICB) response; however, precision biomarker-driven, placebo-controlled trials are lacking. We performed a multicenter, randomized placebo-controlled, biomarker-stratified phase I trial in patients with ICB-naïve metastatic melanoma using SER-401, an orally delivered Firmicutesenriched spore formulation. Fecal microbiota signatures were characterized at baseline; patients were stratified by high versus low Ruminococcaceae abundance prior to randomization to the SER-401 arm (oral vancomycin-preconditioning/SER-401 alone/nivolumab + SER-401), versus the placebo arm [placebo antibiotic/placebo microbiome modulation (PMM)/nivolumab + PMM (NCT03817125)]. Analysis of 14 accrued patients demonstrated that treatment with SER-401 + nivolumab was safe, with an overall response rate of 25% in the SER-401 arm and 67% in the placebo arm (though the study was underpowered related to poor accrual during the COVID-19 pandemic). Translational analyses demonstrated that vancomycin preconditioning was associated with the disruption of the gut microbiota and impaired immunity, with incomplete recovery at ICB administration (particularly in patients with high baseline Ruminococcaceae). These results have important implications for future microbiome modulation trials. Significance: This first-of-its-kind, placebo-controlled, randomized biomarker-driven microbiome modulation trial demonstrated that vancomycin + SER-401 and anti-PD-1 are safe in melanoma patients. Although limited by poor accrual during the pandemic, important insights were gained via translational analyses, suggesting that antibiotic preconditioning and interventional drug dosing regimens should be carefully considered when designing such trials.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Glitza IC, Seo YD, Spencer CN, et al. Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Cancer Discov. 2024. PMID: 38588588. doi:10.1158/2159-8290.CD-24-0066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。